Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen (FLUID)

Participants: treatment-naïve active subfoveal CNV secondary to AMD

• n=279

Intervention:

Group 1 (intensive arm): Ranibizumab 0.5mg monthly until complete resolution of SRF and intraretinal fluid
Group 2 (relaxed arm): Ranibizumab 0.5mg monthly until resolution of intraretinal fluid only before extending treamtent intervals

The relaxed treatment arm demonstrated non-inferior BCVA improvement from baseline to month 24 compared with the intensive treatment arm.

Participants in the relaxed group received fewer ranibizumab injections over 24 months than those in the intensive group (mean 15.8 vs 17).